Fig. 1

Fig. 1. From: Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients.

1 Octreotide LAR 30 mg, 2a Pegvisomant 40 mg daily, 2b Pegvisomant 30 mg daily, 3a and b Somatuline autosolution and Pegvisomant

Sebastian J. C. M. M. Neggers, et al. Pituitary. 2011 September;14(3):253-258.

Supplemental Content

Filter your results:

Search details

See more...

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk